Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-04805712
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-04805712 is an experimental small molecule drug developed by Pfizer. It was investigated in a Phase 1 clinical trial to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. The trial involved ascending single and multiple oral doses of the compound. No mechanism of action or therapeutic target has been publicly disclosed for this compound, and there are no approved indications or known adverse events reported. Development was discontinued after Phase 1 trials were terminated.
- Other names
- PF-4805712PF4805712PF 4805712
02
Targets
LTA4H (Leukotriene A4 hydrolase)
Beyond the preview
Go deeper on PF-04805712.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-04805712.